Briggs W. Morrison, M.D., who was born on June 1, 1968, has built a solid career in the medical field, holding an M.D. and a Ph.D. from the University of Pennsylvania. He led Syndax Pharmaceuticals as CEO for several years...

Briggs W. Morrison, M.D., who was born on June 1, 1968, has built a solid career in the medical field, holding an M.D. and a Ph.D. from the University of Pennsylvania. He led Syndax Pharmaceuticals as CEO for several years until he transitioned to President and Head of Research and Development in early 2022. His experience in the pharmaceutical industry has shaped his leadership style, focusing on innovative drug development. Dr. Morrison has a well-defined compensation strategy that relates strongly to company performance, with a notable peak total pay of over $2 million in 2020. His commitment to the company is evident, as he recently agreed to serve as an advisor after stepping down from his CEO role. Key performance metrics that drive his compensation include revenue growth and operational success. This approach resonates with his goal of long-term value creation. Dr. Morrison’s leadership reflects his deep knowledge in medicine and a strategic vision for advancing pharmaceutical research.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Syndax Pharmaceuticals CEOs

S

Briggs W. Morrison, M.D.

Ex-CEO of Syndax Pharmaceuticals

Education

M.D. from University of Pennsylvania, Ph.D. from University of Pennsylvania

Field of Expertise

Healthcare & Life Sciences - Medicine

Sector of Economy

Healthcare

Born

June 1, 1968 - 57 years ago

CEO of Syndax Pharmaceuticals for

6 years 4 months (Oct 2015 - Feb 2022)

Previous Experience

Chief Executive Officer and Director at Syndax Pharmaceuticals, Inc.

Rivals

Competitors/colleagues of Briggs W. Morrison, M.D.

Holdings

See how much did Briggs W. Morrison, M.D. make over time.

Dr. Morrison has made significant holdings at Syndax Pharmaceuticals. He once held RSUs worth approximately $1.26 million when they vested in 2020. At his peak in 2021, his holdings were substantial, but he has since focused more on his research...

Dr. Morrison has made significant holdings at Syndax Pharmaceuticals. He once held RSUs worth approximately $1.26 million when they vested in 2020. At his peak in 2021, his holdings were substantial, but he has since focused more on his research and development responsibilities. His investments have seen highs and lows, reflecting the volatility in the pharma sector. Currently, he continues to benefit from his equity awards as he transitions into a new role within the company, keeping alignment with his long-term interests in Syndax.

No data yet.

Total Stock Sold

$28.89M

SNDX

$26.07M

1,210,884 SNDX shares

ARVN

$2.82M

41,920 ARVN shares

What if they kept their stock?

If Briggs W. Morrison, M.D. didn't sell their stock, today they would have:
Extra SNDX1,210,884 shares worth $17.92M and ARVN41,920 shares worth $1.48M.
This is -32.83% and $9.48M less than what they got when they sold the stock.

Insider Trading

See recent insider trades of Briggs W. Morrison, M.D..

ARVN

5,899 shares

ARVN

May 29, 2024

Received

SNDX

17,000 shares

SNDX

Feb 7, 2024

Received

SNDX

$965.40K

SNDX at $18.27/share

Aug 9, 2023

Sale

SNDX

$1.08M

SNDX at $20.40/share

Jul 10, 2023

Sale

ARVN

4,121 shares

ARVN

Jun 15, 2023

Received

SNDX

$1.12M

SNDX at $21.18/share

Jun 9, 2023

Sale

SNDX

$1.13M

SNDX at $21.41/share

May 9, 2023

Sale

SNDX

$1.03M

SNDX at $19.53/share

Apr 10, 2023

Sale

SNDX

$1.19M

SNDX at $22.53/share

Mar 13, 2023

Sale

SNDX

$1.42M

SNDX at $26.83/share

Feb 6, 2023

Sale

Compensation History

See how much did Briggs W. Morrison, M.D. make over time.

In 2022, Dr. Morrison's total compensation was about $575,000, including a salary of $450,000 and a performance-based bonus of $100,000. He had a decent payout from vested stock units worth $75,000, which shows the connection between his earnings and the company's performance metrics focused on strategic objectives. Over the years, his compensation has fluctuated significantly, reaching a peak in 2020 when he earned over $2 million, primarily driven by high stock option values and bonuses linked to company growth. His compensation philosophy aligns with ensuring the long-term sustainability and success of Syndax Pharmaceuticals, emphasizing performance and retention.

Year

2022

Total Compensation

$650.00K

Salary

$450.00K

Board Justification

The compensation philosophy is designed to align executive pay with company performance, focusing on long-term value creation and retention of key talent.

Bonus

$100.00K

Board Justification

The bonus is based on the company's performance metrics, including revenue growth and operational milestones achieved in 2022.

Other

$25.00K

Board Justification

Other compensation includes health benefits and retirement contributions.

Restricted Stock

$75.00K(5K RSU)

Board Justification

5,000 shares of restricted stock units (RSUs) vested in 2022, which were granted in prior years based on performance criteria.

Performance Metrics

Performance metrics include revenue targets, operational milestones, and overall company growth.

Other Syndax Pharmaceuticals CEOs

Here are other CEOs of Syndax Pharmaceuticals

Michael A. Metzger

CEO of Syndax Pharmaceuticals

February 2022 - Present